Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAVMET: maraviroc and/or metformin for hepatic steatosis in HIV-1-infected adults
2016-003575-21Phase 2Unknown
- Sponsor
- MRC Clinical Trials Unit at UCL
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of aprepitant and metformin in steatosis, metabolic dysfunction-associated steatotic liver disease (MASLD) and human immunodeficiency virus infection (HIV) (4 arms), sponsored by MRC Clinical Trials Unit at UCL. Primary endpoint: Change in percentage of liver fat. Status: unknown.
02
Drugs
aprepitantmetformin
03
Conditions
steatosismetabolic dysfunction-associated steatotic liver disease (MASLD)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2016-003575-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003575-21.